BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY

File: 120396_sep96_decls73_0003.txt
Page: 0003
Total Pages: 10

Subject: BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY                  

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY                                                  

Document Number:          1

Folder SEQ  #:         66





                 Security and proximity to the U.S. Army Medical Research and
             Development Command, the major medical biological defense base,
             and availability of land makes Fort Detrick a possible location
             for the proposed facility.


                 Production priorities will be established IAW threat and DOD
             guidance. It is likely that the VPF will begin with vaccines
             already being produced and then address vaccines in development
             or vaccines no longer in commercial production. This strategy
             has many advantages. First, it will give DOD the surge
             capability and production flexibility it currently lacks.
             Second, it allows DOD and FDA time to develop the required
             procedures and Memorandum of Agreements, as necessary.
             Successful production of existing vaccines will demonstrate
             technical competence, the ability to conform with complex
             regulatory requirements, and fulfills all generic requirements.

             ACOUISITION STRATEGY.   A initial design study has already been
             started by the Corps of Engineers in coordination with the Health
             Facilities Planning Agency. The study will be completed August
             1993. This will provide the details necessary to begin the
             formal design process. It will also define the personnel and
             other requirements.

                 Funds have already been programmed by the Army. An
             environmental assessment and economic analysis will, begin ,hortly
             after the design start. The environmental assessment and 35
             percent of the final design submission is to occur in PY94 so
             that construction can take place in FY95. Construction is
             projected to take two to three years. Pilot lot production and
             FDA review will begin FY97. Vaccines will then be entered into
PY98/99.





             SOURCE: )W KLENXE, DASG-HCD, (703) 756-8163













                                             3

Document 10 f:/Week-36/BX003203/BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY/biological defense vaccine production facility:11259610130813
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY
Folder Seq # = 66
Subject = BIOLOGICAL DEFENSE VACCINE PRODUCTION FACILITY
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 25-NOV-1996